INTRODUCTION AND OBJECTIVES: Radical Nephroureterectomy (RNU) is the gold standard treatment for Upper Tract Urothelial Carcinoma (UTUC). However, less invasive treatment modalities exist for low grade, non-invasive tumors. Determination of tumor characteristics are currently based on endoscopic biopsies, which often supply insufficient tissue for accurate diagnosis. Biochemical analysis of UTUC biopsies may enable practitioners to make more informed clinical decisions and avoid overtreating less aggressive tumors. We propose that by comparing microRNA (miRNA) expression patterns from UTUC biopsies to their final pathology from RNU samples we may provide a framework for more effective diagnosis, and possibly help predict tumor behavior.
METHODS: Under an IRB-approved study, total RNA was extracted from formalin-fixed, paraffin-embedded UTUC biopsy samples from 64 patients who subsequently underwent RNU from 2005-2018 at two high-volume institutions. Twenty samples were profiled via miRNA RT-qPCR and screened with an array for 752 unique miRNAs. Differentially expressed miRNAs were then selected for validation using 44 UTUC biopsy samples. In total, 28 high grade (HG) and 16 low grade (LG) samples were analyzed using ROC curves and logistic regression analysis to establish a predictive miRNA model corresponding to final pathological grade and stage after RNU.
RESULTS: Screening array analysis identified 26 miRNAs differentially expressed between LG and HG tumors (p<0.05 and FDR<0.1). Of these, four were up-regulated and 22 were downregulated in the HG, invasive tumors. Hierarchical clustering analysis INTRODUCTION AND OBJECTIVES: Upper tract urothelial carcinoma (UTUC) is a rare but aggressive urologic malignancy. Nephroureterectomy (NU) can be curative for organ confined disease. However, 30-50% of patients will develop intravesical recurrence, which is associated with higher cancer specific and overall mortality. Bladder surveillance is costly and time consuming. Single dose intravesical therapy at the time of NU decreases bladder recurrences but has potential toxicity so targeting those at highest risk would be useful. MicroRNAs (miRNA) are biomarkers with potential to differentiate behavior of cancers. Identification of miRNA associated with intravesical recurrence could improve screening and treatment algorithms after NU. We sought to identify miRNA associated with intravesical recurrence after NU for UTUC.
METHODS: Total RNA was extracted from formalin-fixed, paraffin-embedded NU samples from 2005 to 2013 under a multiinstitutional IRB-approved study. Patients were excluded if they had history of or synchronous diagnosis of bladder cancer. Samples were categorized as either having a bladder recurrence after NU or not having a bladder recurrence within 12 months of NU. Twenty patients were selected for an initial miRNA screening study. Each group consisted of a representative sample of patients by gender, age, tumor grade (high or low), and pathological stage (Ta-T4). Samples from each group were profiled via miRNA RT-PCR array.
RESULTS: Eleven samples from the recurrence group and 9 from the non-recurrence group underwent array analysis. Demographics and baseline characteristics were similar between groups. Array analysis of 752 miRNA identified 21 miRNA that were differentially expressed (FDR<0.1) including 8 miRNA with greater than 2 fold differential expression between the recurrence and nonrecurrence groups. Specifically, miR-30b-5p discriminated between the groups with a 91% sensitivity, 67% specificity, and an AUC[0.808. Several of the miRNA we identified have been previously implicated in urologic cancers.
CONCLUSIONS: Distinct miRNA expression profiles were associated with patients with or without subsequent intravesical urothelial cancer recurrence after NU for UTUC. This study is among the first to identify molecular biomarkers that correlate with intravesical recurrence after NU. This miRNA profile will be validated in a larger cohort. Patients with this miRNA profile may merit receipt of single dose intravesical therapy, and/or shorter screening cystoscopy intervals after NU.
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PD62-10 TOPICAL TREATMENT FOR HIGH-GRADE UPPER TRACT CYTOLOGY WITH NEGATIVE IMAGING (HGUTCNI)
Andrew Vitale*, Jeremy West, Brenton Sherwood, Kenneth Nepple, Sarah Mott, Michael O'Donnell, Iowa City, IA INTRODUCTION AND OBJECTIVES: The standard of care for high-grade Upper Tract Urothelial Carcinoma has been nephroureterectomy (NU) with excision of a bladder cuff. However, no specific guidelines exist for the management of localizing high grade cytology for which no visible lesions are apparent. Topical therapy may be appropriate in such patients.
METHODS: Data was collected retrospectively on patients with HGUTCNI receiving upper tract treatments (UTT). Induction treatment regimens included weekly BCG þ interferon (IFN) X 6, BCG þ IFN þ IL2 þ GMCSF (quad immunotherapy) X 6, sequential gemcitabine/docetaxel (gem/doce) X 6, and a 4-drug regimen of sequential adriamycin and gemcitabine alternating weekly with sequential mitomycin and docetaxel (quad chemo) X 8. Responders underwent one 3 week maintenance cycle for BCG regimens and 6 once monthly maintenance treatments for chemo regimens. Patients were preferentially treated with a BCG regimen unless previously BCG unresponsive whereupon gem/doce followed by quad chemo were used. After induction, patients were restaged with cystoscopy and cytology from the bladder and upper tracts, upper tract imaging and ureteroscopy. Recurrencefree survival was calculated from time of treatment to recurrence based on Kaplan-Meier plots.
RESULTS: Sixty-six patients received UTT for HGUTCNI; 43 of these had coexistant bladder cancer recurrences (65%). 38 patients (57%) had upper tract recurrence of which 13 underwent NU (20%), 9 were not surgical candidates or refused NU (14%), and 8 developed metastatic disease (12%). At median follow-up of 44 months, 22 patients (34%) died with 14 (21%) attributable to urothelial carcinoma. Overall UT recurrence free survival (RFS) at 1 year was 64%. Patients receiving BCG, Quad BCG, Gem/Doce, or Quad Chemo had 1-year RFS rates of 67%, 67%, 91% and 33%, respectively (see Figure) . At 24 months, RFS for patients receiving any BCG was 61% and the median time to recurrence was >57 months.
CONCLUSIONS: Topical treatment may provide durable RFS in patients with HGUTCNI, however, close follow up is necessary as progression and even metastasis is possible from both coexistant bladder cancer and UT disease.
